| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We examined whether it was possible to detect EGFR mutations in cytology cell-free DNA (ccfDNA) from the supernatant fluids of bronchial and effusion cytology samples. Quantity and fragmentation of ccfDNA in the supernatant fluid and cell damage and CC3 expression in the sediment gradually increased in a time dependent manner in the cell lines. In the 74 clinical samples, the detection of EGFR mutations using ccfDNA showed a high sensitivity in samples with malignant cells. In contrast, EGFR mutations were not found in negative samples. The twenty-two patients of EGFR mutations were detected in 63.6% of ccfDNA from supernatant fluids. EGFR mutations were found in 81.3% (13/16) of malignant cell patients, whereas EGFR mutations were not found in the negative samples. Our results suggest that ccfDNA might help to compensate for the lack of adequate DNA in EGFR mutation analysis, and ccfDNA supernatant fluids can be used to detect EGFR mutation in the same way as cancer cell sediments.
|
